Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-α to patients with soft tissue limb sarcoma

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 317-322

  Mocellin, Simone ^a   Provenzano, Maurizio ^b   Lise, Mario ^a   Nitti, Donato ^a   Rossi, Carlo Riccardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Quantitative real time PCR; Soft tissue sarcoma; TIA 1; TNF

Indexed keywords

DOXORUBICIN; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FIBROBLAST; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOTHESIS; IN VIVO STUDY; LIMB; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; TIA 1 GENE; TREATMENT OUTCOME; TUMOR BIOPSY;

ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DNA PRIMERS; DOXORUBICIN; ENDOTHELIUM, VASCULAR; FIBROBLASTS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICROCIRCULATION; POLY(A)-BINDING PROTEINS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; RNA-BINDING PROTEINS; SARCOMA; SOFT TISSUE NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141746187     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11369     Document Type: Article

References (32)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
2. Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza M, Azzarelli A, Pilati P, Mocellin S, Lise M. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999;86:1742-9.
3. Nooijen PT, Eggermont AM, Schalkwijk L, Henzen-Logmans S, de Waal RM, Ruiter DJ. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res 1998;58:4880-7.
4. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.
5. Duerksen-Hughes PJ, Day DB, Laster SM, Zachariades NA, Aquino L, Gooding LR. Both tumor necrosis factor and nitric oxide participate in lysis of simian virus 40-transformed cells by activated macrophages. J Immunol 1992;149:2114-22.
6. Kwak JY, Han MK, Choi KS, Park IH, Park SY, Sohn MH, Kim UH, McGregor JR, Samlowski WE, Yim CY. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol 2000;203:84-94.
7. Gnant MF, Berger AC, Huang J, Puhlmann M, Wu PC, Merino MJ, Bartlett DL, Alexander HR, Libutti SK. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res 1999;59:4668-74.
8. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998;10:573-80.
9. Estrada C, Gomez C, Martin C, Moncada S, Gonzalez C. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem Biophys Res Commun 1992;186:475-82.
10. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
11. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL,. ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82:973-80.
12. Cox GW, Melillo G, Chattopadhyay U, Mullet D, Fertel RH, Varesio L. Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity. J Immunol 1992;149:3290-6.
13. Blankenstein T, Qin ZH, Uberla K, Muller W, Rosen H, Volk HD, Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
14. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991;173:869-79.
15. Ostensen ME, Thiele DL, Lipsky PE. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol 1987;138:4185-91.
16. Rossi CR, Vecchiato A, Foletto M, Nitti D, Ninfo V, Fornasiero A, Sotti G, Tregnaghi A, Melanotte P, Lise M. Phase 11 study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-6.
17. Mocellin S, Ohnmacht GA, Wang E, Marincola FM. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer 2001:93:236-42.
18. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000;92:1336-44.
19. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-5.
20. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-9.
21. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola F. Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001;167:1809-20.
22. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21:33-7.
23. Wang E, Marincola FM. cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J 2001;7:16-24.
24. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
25. Beck AR, Medley QG, O'Brien S, Anderson P, Streuli M. Structure, tissue distribution and genomic organization of the murine RRM-type RNA binding proteins TIA-1 and TIAR. Nucleic Acids Res 1996;24:3829-35.
26. Forch P, Valcarcel J. Molecular mechanisms of gene expression regulation by the apoptosis-promoting protein TIA-1. Apoptosis 2001;6:463-8.
27. Kedersha N, Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans 2001;30:963-9.
28. Forch P, Puig O, Kedersha N, Martinez C, Granneman S, Seraphin B, Anderson P, Valcarcel J. The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. Mol Cell 2000:6:1089-98.
29. Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B, Chen S, Gueydan C, Kruys V, Streuli M, Anderson P. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 2000;19:4154-63.
30. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6.
31. Pober JS. Activation and injury of endothelial cells by cytokines. Pathol Biol 1998;46:159-63.
32. Moretta L, Bottino C, Pende D, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: their origin, receptors and function. Eur J Immunol 2002;32:1205-11.